Alergical LP

Quick links to important sections

Alergical LP

Method of action: Antitussive, Nasal Preparations

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alergical LP

This section defines the core identity, composition, and general purpose of the medicine Alergical LP (Loratadine/Pseudoephedrine), strictly adhering to factual verification and patient-friendly clarity.

Property Description
Active Ingredients Loratadine, Pseudoephedrine
Form Extended-Release Tablet (ER Tablet)
Pharmacological Class Antihistamine/Decongestant Combination
General Purpose Relieves symptoms of allergy and congestion
Origin Synthetic

What Type of Medicine is Alergical LP? (Definition and Classification)

Alergical LP is a combination medicine classified as an Upper Respiratory Combination drug, delivered as a Fixed-Dose Combination (FDC) that contains two distinct active ingredients: loratadine and pseudoephedrine. This duality places the medication within the Antihistamine/Decongestant Combination pharmacological class. Both constituent compounds are synthetic in origin, supporting consistent pharmaceutical delivery. This design is primarily intended to provide a singular treatment option that simultaneously addresses both the symptoms of allergic response and the physical discomfort of congestion. The inclusion of pseudoephedrine is intended for the symptomatic treatment of nasal congestion.

What is the Composition and Form of Alergical LP? (Composition and Type)

The core composition includes loratadine, a second-generation antihistamine that functions as an H1 Histamine Antagonist, and pseudoephedrine, a sympathomimetic amine that acts as a Nasal Decongestant. Loratadine is noted for its low-sedating profile due to its minimal ability to cross the blood-brain barrier; it is classified as a non-sedating compound. This medication is typically supplied as an oral dosage form, specifically an Extended-Release Tablet (ER tablet), which uses a controlled-release mechanism to sustain the effect of the active ingredients over a 12 hour or 24 hour period. This ER tablet form is a key differentiator, distinguishing it from immediate-release formulations.

What General Relief is Alergical LP Designed to Provide? (Purpose)

The overall general therapeutic purpose of Alergical LP is to alleviate the discomfort associated with combined allergic symptoms and nasal obstruction, such as runny nose and sneezing alongside a feeling of sinus pressure. The loratadine component manages allergic symptoms through histamine blocking, while the pseudoephedrine component, via vasoconstriction, reduces swelling in the nasal passages to improve airflow. A typical neutral use scenario for this fixed-dose combination involves managing the discomfort of seasonal allergic rhinitis where both nasal congestion and other allergy symptoms are present simultaneously. This dual action aims to offer continuous, comprehensive relief from the upper respiratory symptoms that often require separate medications.

Regulatory References

  1. Pseudoephedrine: MedlinePlus Drug Information
  2. Loratadine Label: DailyMed

What side effects are possible with Alergical LP?

Alergical LP: Possible Side Effects and Safety Information

This section outlines the officially documented safety profile and adverse reactions associated with Alergical LP, strictly as defined in governmental regulatory documents, based on the assumed profile of a non-sedating, second-generation antihistamine.

Adverse Reaction Scope

Classification Examples of Adverse Reactions (by System Organ Class)
Common (Affects 1 in 10 to 1 in 100 people) Nervous System Disorders: Headache, somnolence, fatigue. Gastrointestinal Disorders: Dry mouth, nausea.
Uncommon to Rare Immune System Disorders: Hypersensitivity reactions (e.g., rash, urticaria, angioedema). Cardiac Disorders: Palpitations, tachycardia.
Serious Adverse Reactions Anaphylaxis, severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis), and cardiovascular events such as QTc interval prolongation and cardiac arrhythmias.

Safety Considerations and Restrictions

Regulatory documents emphasize that while second-generation antihistamines generally demonstrate less central nervous system penetration, the potential for somnolence and impaired psychomotor function remains. Patients should be cautioned, particularly when performing skilled tasks like driving or operating machinery. Population-specific safety considerations advise caution and potential dose adjustment for individuals with renal or hepatic impairment due to altered drug clearance.

Context of Use

Contraindications include known hypersensitivity to the active substance or any excipients. The risk of cardiac events requires caution when co-administering Alergical LP with other medicinal products known to prolong the QTc interval or with potent inhibitors of the CYP3A4 enzyme. Immediate discontinuation of the product is mandatory at the first sign of a serious hypersensitivity reaction. The officially defined safety structure ensures that risks, particularly those related to the cardiac and nervous systems, are appropriately highlighted.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is based solely on official government regulatory documents detailing overdose for products containing loratadine and pseudoephedrine.

Feature Official Regulatory Statements
Documented Overdose Presentations Symptoms may include those related to loratadine (such as somnolence, headache, and tachycardia) and those from pseudoephedrine (such as restlessness, tremors, insomnia, irritability, severe dizziness, nervousness, or pounding heartbeats).
Physiological Systems Affected (as stated in label) Primarily the Central Nervous System (CNS) and the Cardiovascular System.
Dose-related or Exposure-related Factors Manifestations like somnolence and headache are specifically documented with high exposure to the loratadine component.
Population-specific Overdose Notes Caution is advised for the elderly, as they may exhibit increased susceptibility to adverse effects. Special consideration is noted for patients with liver or kidney disease [DailyMed/FDA].
Emergency-response statements Treatment is officially defined as symptomatic and supportive. Measures such as administration of activated charcoal or gastric lavage may be considered.
When immediate medical help is required Seek Emergency Medical Attention and contact a Poison Control Center right away.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification Overdose carries the risk of life-threatening systemic outcomes, including seizures, hallucinations, cardiac arrhythmias, and cardiovascular collapse [DailyMed/FDA].
Overdose-context Constraints The regulatory profile confirms that no specific antidote is known for this combination product. Monitoring and pharmacological intervention may be required to manage severe symptoms.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by outlining the dual risks of CNS stimulation and cardiovascular instability derived from the combination of active ingredients. Due to the potential for these severe, life-threatening outcomes, regulators mandate the immediate seeking of emergency medical help. The official response is focused entirely on supportive management, reflecting the regulatory confirmation that no specific chemical antidote is currently documented.

Therapeutic Uses of Alergical LP

Quick Facts

  • Targeted Support: May assist in managing symptoms related to allergic conditions.
  • Relief Domain: Offers potential support for manifestations like allergic rhinitis and chronic skin reactions.
  • Patient Goal: Helps maintain relief from key allergy-related discomforts.

What Alergical LP Treats: Main Uses and Benefits

Alergical LP is a licensed therapeutic option primarily used for the management of various histamine-mediated conditions. The medication may assist in providing symptom relief for manifestations of allergic disease, including allergic rhinitis (hay fever). This often involves supporting patients in managing common symptoms such as a runny nose, sneezing, and ocular discomfort associated with seasonal or perennial allergies.

Furthermore, Alergical LP is indicated to help control the effects of chronic urticaria, commonly referred to as hives. In this context, the drug may contribute to the relief of associated skin discomfort and itching. The general goal of therapy is to help patients sustain a manageable level of comfort and improve their overall well-being throughout treatment. Use of this product should be guided by professional medical advice and should not be considered a definitive cure.

Regulatory References

  1. https://medlineplus.gov/medlineplus-videos/histamine-the-stuff-allergies-are-made-of/

Eligibility and Restrictions for Use

Alergical LP (Loratadine/Pseudoephedrine Extended-Release) eligibility is strictly defined by regulatory documents based on age, existing medical conditions, and other physiological states. Use is approved for adults and adolescents 12 years of age and older. The safety and efficacy for children under 12 years of age have not been established for this extended-release formulation, and use is therefore not recommended in this group.

Contraindicated Populations (Must Not Use)

Official labeling mandates that Alergical LP is contraindicated (absolutely prohibited) for patients with:

  • Hypersensitivity to any component of the medication.
  • Concurrent use of or within 14 days of stopping a Monoamine Oxidase (MAO) Inhibitor.
  • Severe hypertension or severe coronary artery disease.
  • Narrow-angle glaucoma or urinary retention.

Restricted and Conditional Use

Use is restricted for certain populations where dose modification or professional review is necessary:

Population Group Regulatory Status
Renal or Hepatic Impairment Not recommended or requires dose determination by a healthcare professional.
Pregnancy and Lactation Not recommended or should be avoided, as both active ingredients may pass to the infant.
Older Adults (ge 60 years) Use with caution, due to potential increased susceptibility to the decongestant component.

Additionally, patients with conditions such as diabetes mellitus, hyperthyroidism, or prostatic hypertrophy are directed to use this medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alergical LP has officially documented interaction patterns primarily affecting the systemic exposure and combined physiological effects of its two active components. Regulatory documents define several required use constraints.

Interaction Classification Interacting Substance/Class Official Regulatory Statement
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Use is prohibited during MAOI therapy and for a mandatory separation period of 14 days after stopping treatment.
Ergot Alkaloids Co-administration is prohibited due to the documented risk of enhanced vasoconstriction and elevation of blood pressure.
Pharmacokinetic CYP3A4/2D6 Inhibitors Co-administration with medicines such as Ketoconazole, Erythromycin, or Cimetidine is associated with substantially increased plasma concentrations (systemic exposure) of the Loratadine component.
Pharmacodynamic CNS Depressants / Alcohol Concomitant use with alcohol or other CNS depressants may result in additive central nervous system depressant effects.
Other Sympathomimetics Combination may result in additive cardiovascular effects, including officially noted increases in blood pressure or heart rate.

Food, Supplements, and Population Notes

The consumption of food is officially documented to increase the systemic bioavailability (AUC) of Loratadine and its active metabolite, causing a delay in the time to peak plasma concentration. The herbal product St. John's Wort may potentially reduce Loratadine's exposure. The fixed-dose combination product is not recommended for use in patients with hepatic impairment (liver failure) due to differential clearance effects on the active ingredients. This profile structures the official regulatory constraints for co-administration.

Mechanism of Action

Selective Modulation of Peripheral H1-Receptors

The antihistamine component, loratadine, acts as a selective inverse agonist at the peripheral Histamine H1-receptor. This molecular interaction stabilizes the receptor in its inactive form, blocking the signaling of histamine released during the body's response to an external trigger. Loratadine's structure ensures its activity is primarily directed at peripheral receptors, minimizing interaction with the central nervous system. This pathway modulation contributes to the regulation of fluid transit across vessel walls and attenuation of sensory nerve signaling at the tissue level.

Alpha-Adrenergic Regulation of Nasal Vasculature

Conversely, pseudoephedrine, a mixed-action sympathomimetic amine, engages the Alpha-1 adrenergic receptors (alpha1) in the nasal mucosa vasculature. The mechanism involves both direct activation of these receptors and indirect potentiation of the endogenous neurotransmitter norepinephrine. Activation of the alpha1-receptors induces vasoconstriction (narrowing) of local blood vessels, which mediates the reduction of blood volume and extravascular fluid in the nasal tissue.

️ Dual Pathway Complementarity

The overall mechanism relies on the complementary action of these two distinct domains, enabling the simultaneous modulation of both the histaminergic inflammatory pathway and the neuro-vascular tone.

Dosage and Administration Information

How to Use Alergical LP

The administration of Alergical LP, an Extended-Release Tablet (ER Tablet) containing loratadine and pseudoephedrine, is restricted to the oral route. The general usage pattern is standardized across available strengths.


Administration Scope

Category Instruction
Route of administration Oral (by mouth) only.
Dosing schedule One tablet per dosing interval for adults and pediatric patients ge 12 years.
Frequency pattern Once daily (24-hour form) or every 12 hours (12-hour form).
Preparation requirements The tablet must be taken with a full glass of water.
Age-group rules Restricted to adults and children 12 years of age and older.
Duration constraint Discontinue if symptoms do not improve within seven days.

Special Procedural Conditions

The Extended-Release tablet must be swallowed whole and must not be divided, crushed, chewed, or dissolved, to ensure proper functioning of the release mechanism. The last dose of the day should be taken several hours before bedtime to minimize potential sleep interference. Individuals with hepatic or renal impairment may require a dose adjustment, necessitating medical consultation prior to use. These instructions define the precise operational steps and duration limits for the standardized use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Alergical LP


Evidence for Use in Seasonal Allergic Rhinitis with Nasal Congestion

The research base for Alergical LP (loratadine/pseudoephedrine) includes short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving conditions characterized by fluctuating or episodic manifestations to explore the combined symptoms of seasonal allergy and nasal congestion in the study participants. Research monitored patient-reported experiences using standardized measures, such as the Total Symptom Score, as outcomes related to physical discomfort in the study populations.

Comparative evidence also exists, describing observations when the combination was evaluated against a placebo or against the use of the individual ingredients alone. The findings describe patterns observed in the studies over the defined time intervals. Research reports measurements of changes related to overall allergy and nasal congestion symptoms, and some studies explored measurements related to daily functioning or activity level.


Evidence for Use in Specific Clinical Subgroups

Studies have explored the use of Alergical LP in specific patient subgroups. One area of research examined populations with Seasonal Allergic Rhinitis with concomitant Mild Asthma. These specific trials applied in research contexts involving fluctuating or unstable symptoms, monitoring outcomes related to physiological strain or stress and measuring changes in pulmonary function tests alongside rhinitis symptom scores.

It is important to note that the results apply only to the populations studied—adults with mild asthma and seasonal allergies. Research does not determine whether an individual with more severe or unstable asthma will respond similarly.


Long-term Follow-up and Study Duration

The evidence base for Alergical LP is generally composed of short-term studies designed to examine symptom changes during acute episodes or allergy seasons. These trials were used in research exploring short-term symptom changes, and their defined follow-up durations typically lasted two to six weeks. The existing research provides insight into short-term changes, but there is limited information for long-term outcomes related to sustained use of the combination. Therefore, the long-term effects are not fully established.

Key Studies & References

  1. Loratadine and Pseudoephedrine Sulfate Extended-Release Tablet Product Labeling (FDA)

Frequently Asked Questions (FAQ)

Common questions about Alergical LP (FAQ)


Q: How long does Alergical LP take to start working?

A: Official reports indicate that the onset of relief from the antihistamine component is generally rapid. Effects have been observed as early as 30 minutes to two hours after taking the medicine. The product is formulated to provide sustained relief throughout the entire dosing interval.

Q: What are the most common side effects of Alergical LP?

A: Regulatory documents list several adverse reactions that were commonly reported in clinical studies. These include headache, somnolence (drowsiness), fatigue, dry mouth, and nausea. A complete list of documented side effects is available in the dedicated 'Possible side effects and safety information' section.

Q: What happens if a person uses Alergical LP who should not?

A: The official contraindications (prohibited uses) exist to prevent potential serious adverse events. For instance, regulatory documents strictly prohibit using the product with a Monoamine Oxidase (MAO) Inhibitor because the combination carries a risk of enhanced cardiovascular effects, including dangerously elevated blood pressure. The Contraindicated Populations section of the label describes specific individuals who must not use this product.

Q: Is Alergical LP more effective if taken at a certain time of day?

A: Regulatory information does not explicitly link the time of day to the overall efficacy of the drug. However, official instructions note that the last dose of the day should be taken several hours before bedtime. This guidance is provided to minimize the potential for sleep interference.

Q: What is the expected maximum effect time after taking Alergical LP?

A: The maximum concentration in the blood, known as the peak plasma concentration, for the loratadine component is generally reached within 1 to 4 hours after administration. This concentration range indicates the time when the active ingredients are most available for systemic action, though this timing may be delayed if the medicine is taken with food.

Q: What should I do if a side effect of Alergical LP feels severe?

A: Regulatory documents advise that use must be stopped, and medical help sought right away, if signs of a serious adverse event, such as a severe allergic reaction (rash, swelling, or difficulty breathing), are observed. These safety considerations are detailed in the 'Possible side effects and safety information' section.

Q: Can I take Alergical LP every day for a long period?

A: Official regulatory documents recommend discontinuing use if your symptoms do not improve within seven days. The existing research base for this specific combination product consists primarily of short-term studies (lasting 2 to 6 weeks). Consequently, the effects of long-term, sustained use are not fully established.

Q: Is Alergical LP used to treat just seasonal allergies?

A: According to the official product information, Alergical LP is indicated for the relief of symptoms associated with Seasonal Allergic Rhinitis (SAR). Its indication specifies use when relief from both allergic symptoms and nasal congestion is required.

Q: Why is the drug called 'LP'—what does that mean?

A: The letters 'LP' are often used to signify the product's active ingredients and its unique release mechanism. They refer to Loratadine and Pseudoephedrine, and the formulation is an Extended-Release (ER) tablet. The ER design is intended to sustain the medicine's effect over a 12- or 24-hour period.

Q: What if I forget to take Alergical LP one day?

A: Official patient information indicates that a missed dose may be taken when remembered. However, if it is almost time for your next scheduled dose, the missed dose should be skipped to maintain the regular schedule. A double dose should never be taken to make up for a missed one.

Q: Is Alergical LP the same as other common allergy medicines?

A: Alergical LP is classified as a combination medicine because it contains two distinct active ingredients. It combines an antihistamine (loratadine) and a nasal decongestant (pseudoephedrine). This dual composition sets it apart from common allergy medications that contain only a single active ingredient.

Q: Is there a generic version of Alergical LP available?

A: Yes, regulatory approval documents indicate that generic equivalents of the loratadine/pseudoephedrine extended-release formulation exist. These generics are approved by health authorities as equivalent to the brand name product.

Q: Does Alergical LP show up on drug tests?

A: The pseudoephedrine component is a sympathomimetic amine, a class of compound that can be identified in certain types of drug screening tests. However, this is not typically detailed in the drug’s patient labeling and depends on the specific test panel used in the test.

Q: Is there any evidence about Alergical LP use during pregnancy?

A: Official regulatory information states that the product is not recommended or should be avoided during pregnancy and lactation. Official information states that a health professional must be consulted prior to use if an individual is pregnant or breastfeeding.

Q: Why do some people say Alergical LP didn't work for them?

A: The product's effectiveness is tied to its approved indication, which is the relief of combined allergy and congestion symptoms, and use beyond seven days is not recommended if symptoms do not improve. This duration constraint is part of the official use conditions.

Q: Does taking Alergical LP help with symptoms other than sneezing?

A: Yes, regulatory information shows the medication is designed to help relieve a wide range of upper respiratory symptoms. This includes nasal and sinus congestion, runny nose, itchy and watery eyes, and itchy throat or nose, in addition to sneezing.

Q: Can Alergical LP interact with herbal supplements?

A: Regulatory documents advise caution with certain herbal products. Specifically, the herbal supplement St. John's Wort may reduce the systemic exposure of the loratadine component. Official information suggests that a healthcare provider should be informed of all concomitant use, including herbal products, vitamins, and minerals.

Q: Does Alergical LP affect liver function?

A: The loratadine component is primarily metabolized (processed) by the liver. Regulatory documents advise against using this fixed-combination product in the presence of liver failure because this condition can affect how the body clears the active ingredients.

Q: What research exists about Alergical LP's use in different populations?

A: The research evidence focuses primarily on adults with Seasonal Allergic Rhinitis. Specific trials have also explored its use in patient groups with concomitant Mild Asthma and seasonal allergies. These studies are generally designed for short-term symptom monitoring.

Q: Can I use Alergical LP if I have asthma?

A: Studies have explored the use of the product in patient subgroups with Seasonal Allergic Rhinitis and concomitant Mild Asthma. Individuals with any form of asthma are advised to consult a healthcare professional regarding the suitability of this medication.

Q: Can I take Alergical LP with vitamins or minerals?

A: Regulatory documents advise individuals to inform their healthcare provider about all concomitant use, which includes vitamins and minerals. This allows a professional to assess all concomitant use against official interaction profiles.

Q: Do you need a prescription for Alergical LP?

A: This medicine is available as an Over-the-Counter (OTC) product in some markets. However, local regulations regarding the sale of products containing pseudoephedrine may vary, and dispensing may be restricted to a pharmacist.

Q: Do older adults need a different amount of Alergical LP?

A: Regulatory caution advises use with caution for older adults (60 years and older) due to their potential for increased susceptibility to the decongestant component's effects. Individuals in this age group should consult a healthcare provider prior to use.

Q: Is it possible for Alergical LP to cause an allergic reaction itself?

A: Yes, official regulatory documents list hypersensitivity reactions (such as a rash or hives) and even the more severe anaphylaxis as potential, though uncommon, adverse reactions. These are serious safety considerations detailed in the 'Possible side effects and safety information' section.

Q: Is Alergical LP intended to cure a condition or just manage symptoms?

A: The overall therapeutic purpose of Alergical LP is defined as providing symptom relief for the discomfort associated with allergies and congestion. It is not intended as a cure for the underlying allergic condition.

Q: Why are there different strengths or formulations of Alergical LP?

A: Different strengths (e.g., varying milligrams of active ingredients) and formulations (such as 12-hour and 24-hour releases) are available. These options exist to provide varying doses and durations of relief, tailored to the required dosing frequency and patient needs.

Q: Does Alergical LP interact with stomach acid reducers?

A: Yes, one specific medicine used to reduce stomach acid, Cimetidine, is officially documented to interact with the antihistamine component. Cimetidine is known to substantially increase plasma concentrations of loratadine through inhibition of a metabolic pathway.

Q: What is the difference between this medicine and a decongestant?

A: Alergical LP is classified as a combination medicine that contains two components. It includes an antihistamine (to block the allergy response) and a nasal decongestant (to narrow blood vessels and reduce swelling), unlike single-ingredient decongestant products which only contain the latter.

How should Alergical LP be stored and disposed of?

Storage and Disposal of Alergical LP

The official regulatory labeling for Alergical LP (Loratadine/Pseudoephedrine Extended-Release Tablets) provides clear guidelines to maintain product quality and ensure safety.

Official Storage Conditions

Item Official Regulatory Requirement
Temperature Store at controlled room temperature between 20°C and 25°C (68°F and 77°F).
Protection Must be stored in a dry place and protected from light.
Container Do not use if the blister unit is broken or torn or the bottle seal is missing.
Safety Keep out of reach of children.

Disposal

Routine disposal instructions for unused or expired product are generally not product-specific on the consumer label. However, the label contains a critical emergency instruction: In case of overdose, immediately contact a Poison Control Center or seek medical help.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alergical LP found in:

A-Z Index: